Novel 18F-labelled Molecular Probes for Indirect CAR T-cell Tracking with Positron Emission Tomography

Dr Ran Yan (primary)
Imaging chemistry and biology
King's College London
John Maher (secondary)
Research Oncology
King's College London


Chimeric antigen receptor (CAR) based immunotherapies offer a novel and rapidly developing technology that has great potential to ameliorate human disease. One fundamental challenge in the successful development and clinical application of CAR T-cells is the need to better understand the in vivo behaviour of adoptively infused cells. We aim to develop novel 18F-labelled PET tracers to dynamically track the persistence, migration, proliferation, and final fate of the infused CAR T-cells on a patient-by-patient basis. Thus, the new cell tracking probe would provide early insight into the safety, mechanism of action, and efficacy of CAR T-cell therapies.


[1] Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 2012, 1059–1070;
[2] Wilkie S. et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010, 285, 25538–25544;
[3] Shanafelt, A. B., et al. An immune cell-selective interleukin 4 agonist. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9454–9458.

Molecules, cells and industrial biotechnology
Area of Biology
BiotechnologyChemical Biology
Techniques & Approaches
BiochemistryChemistryGeneticsImage ProcessingMathematics / StatisticsMicroscopy / ElectrophysiologyMolecular Biology